Thrombocytopenia complicates decisions regarding anticoagulation therapy in atrial fibrillation
Thrombocytopenia complicates decisions regarding anticoagulation therapy in atrial fibrillation by creating a challenging balance between bleeding risks and thromboembolic prevention.
The retrieved literature directly supports the claim that thrombocytopenia introduces therapeutic dilemmas and challenges when deciding whether and how to administer anticoagulation for atrial fibrillation.
Kawtharany H, Ghazal M, Rayyan A, Jamal F. Atrial fibrillation post hematopoietic stem cell transplant: incidence, risk factors, and management challenges.. 2026. https://doi.org/10.3389/fcvm.2026.1781484
Paper [0] explicitly states that management of atrial fibrillation is challenged by thrombocytopenia, complicating long-term decisions on anticoagulation.
See more details
Mingot-Castellano ME, Álvarez Román MT, Bastida JM, Butta N, Caballero Navarro G, Canaro Hirnyk M, Entrena Ureña L, Gómez Del Castillo Solano MDC, Ramirez Lopez A, Sánchez González B, Valcarcel Ferreira D, Pascual Izquierdo C. Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia.. 2026. https://doi.org/10.3390/jcm15062273
Paper [3] highlights that thrombocytopenia creates major therapeutic challenges when anticoagulant therapy is indicated for conditions like atrial fibrillation due to the dual hemostatic derangement.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt